RAC 2.20% $1.78 race oncology ltd

Ann: Race Appoints George Clinical for Phase 1 Trial of RC220, page-139

  1. 218 Posts.
    lightbulb Created with Sketch. 81
    Hey Daniel, @Mason14,

    Have either of you come across this specific m6a x cardiovascular failure study?

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263194/

    Mason, I know you’ve worked through and posted a lot on the contrary primary mechanism of FTO inhib x chemo cardio toxic and the secondary cardioprotective mechanism of bisantrene (prefacing M1M), so this article’s commentary on how increased FTO/changes in other m6a agents helps cardiac health markers (i.e improved Ca2+ homeostasis) might be of interest/relevance.

 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.